目的 探讨帕金森病患者色觉辨识功能改变与焦虑和抑郁症状之间的关系。 方法 选取2018年11月至2019年11月大连市友谊医院神经内科帕金森病资料库中确诊的63例帕金森病患者,采用孟塞尔色棋(FMT)、汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)、焦虑自评量表(SAS)、抑郁自评量表(SDS)、医院焦虑抑郁量表(HADS)进行评定。收集患者的年龄、性别、病程、受教育程度、Hoehn-Yahr(H-Y)分期、帕金森统一评分量表第3部分(UPDRSⅢ)评分、左旋多巴剂量、简易精神状态检查(MMSE)评分和蒙特利尔认知评估量表(MoCA)评分作为相关因素,进行相关性分析和多元回归分析。 结果 HAMA、SAS、HAMD、SDS、HADS的焦虑和抑郁评分均与FMT评分相关(r > 0.561, P < 0.001)。患者年龄、H-Y分期、病程、UPDRSⅢ评分、左旋多巴剂量、MMSE评分、MoCA评分是FMT评分的独立影响因素。 结论 帕金森病患者的色觉与焦虑和抑郁相关,患者的年龄、病情严重程度和认知功能损害均影响其色觉功能。

Objective To investigate the correlation between the change of color vision and anxiety or depression in patients with Parkinson's disease (PD). Methods From November, 2018 to November, 2019, 63 PD patients from the PD database of Department of Neurology, Dalian Friendship Hospital were selected, and they were tested with Farnsworth-Munsell 100 Hue Test (FMT), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS) and Hospital Anxiety and Depression Scale (HADS). Their age, gender, course of disease, education level, Hoehn-Yahr (H-Y) stage, Unified Parkinson's Disease Rating Scale part III (UPDRSIII), levodopa dose, and scores of Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were collected as related factors, and anlyzed with correlation analysis and multivariate regression. Results The score of FMT was correlated with the scores of HAMA, SAS, HAMD, SDS, and both HADS anxiety and depression (r > 0.561, P < 0.001). Age, H-Y stage, course of disease, score of UPDRSIII, levodopa dose and scores of MMSE and MoCA were related with the score of FMT independently. Conclusion Color vision dysfunction in PD patients is correlated to the severity of anxiety and depression, and it is affected with age, severity of PD and cognitive impairment.